Crescent

lottie: Interior-Crescent-10-Green / svg: public://2025-01/Crescent 1.2 green left bottom.svg / styles: style="position: absolute; top: -225px; left: -430px; z-index: 5; " / loop: On

Crescent

lottie: Interior-Crescent-13-Green / svg: public://2025-01/Crescent 1.2 green right.svg / styles: style="position: absolute; top: 600px; right: -230px; z-index: 4; " / loop: On

Results in non-ambulatory people

Study 2 included non-ambulatory participants and was designed to measure the amount of ELEVIDYS micro-dystrophin produced and safety. The change in micro-dystrophin levels is shared below, and safety information from all trials can be found here.

A different study is measuring the impact on muscle function, but these results are not available yet.

Average increase in ELEVIDYS micro-dystrophin 3 months after treatment

Across all trials, ambulatory participants produced an average of 34% to 51% ELEVIDYS micro-dystrophin. Non-ambulatory participants produced an average of 40% ELEVIDYS micro-dystrophin.

NON-AMBULATORY

STUDY 2

40%

8 participants

People with Duchenne who are untreated typically have little to no dystrophin.

These results were consistent with what was seen in ambulatory participants. Results were measured using a test called western blot, which looks at a small piece of muscle from a person’s body to see if micro-dystrophin was produced. The numbers reflect the amount produced if 100% was the typical level in a person without Duchenne.

ELEVIDYS micro-dystrophin had a demonstrated impact on motor function in ambulatory people. While motor function data is not yet available for non-ambulatory people, ELEVIDYS was approved under accelerated approval based on the FDA’s belief that increased micro-dystrophin is reasonably likely to have a clinical benefit. More information is needed to confirm if there is a clinical benefit in non-ambulatory people. A clinical trial is ongoing to further evaluate ELEVIDYS in the non-ambulatory population. Safety information in non-ambulatory people is limited to 8 clinical trial participants.

Lotties

1 - src: /sites/default/files/2025-02/pinned%20polaroids%20v2.json / styles: width: 100%; / loop: Off

SEE RESULTS IN AMBULATORY PEOPLE HERE

Next up: Explore safety

Now that you’ve seen the results from the clinical trials, learn more about safety, including possible side effects.

What is ELEVIDYS (delandistrogene moxeparvovec-rokl)?

ELEVIDYS is a prescription gene therapy used to treat ambulatory individuals at least 4 years old with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the DMD gene.

ELEVIDYS is approved under accelerated approval for non-ambulatory patients at least 4 years old with DMD who have a confirmed mutation in the DMD gene. Accelerated approval allows for drugs to be approved based on a marker that is considered reasonably likely to predict a clinical benefit. ELEVIDYS treatment increased the marker, ELEVIDYS micro-dystrophin in skeletal muscle. Verification of a clinical benefit may be needed for ELEVIDYS to continue to be approved for non-ambulatory patients with DMD.

Important Safety Information

Who should not receive ELEVIDYS?
Individuals with certain types of mutations, any deletion in exon 8 and/or exon 9 in the DMD gene, should not receive ELEVIDYS.

What is the most important information to know about ELEVIDYS?
Infusion-related reactions, including hypersensitivity and serious allergic reactions (anaphylaxis), have occurred during and after ELEVIDYS infusion. Symptoms may include fast heart rate, fast breathing, swollen lips, shortness of breath, nostrils widening, hives, red and blotchy skin, itchy or inflamed lips, rash, vomiting, nausea, chills, and fever. Your doctor will monitor you during and at least 3 hours after ELEVIDYS infusion. If an infusion-related reaction occurs, your doctor may slow or stop the ELEVIDYS infusion and provide additional medical treatment as needed. Contact a healthcare provider immediately if infusion-related symptoms occur.

ELEVIDYS can increase certain liver enzyme levels and cause acute serious liver injury. Patients will receive oral corticosteroid medication before and after infusion with ELEVIDYS and will undergo weekly blood tests to monitor liver enzyme levels for 3 months after treatment. Contact a healthcare provider immediately if the patient’s skin and/or whites of the eyes appear yellowish or if the patient misses a dose of corticosteroid or vomits it up.

Administration of ELEVIDYS may be delayed in patients who have acute liver disease until the condition is resolved or under control. Patients with preexisting liver impairment, chronic liver infection, or acute liver disease may be at higher risk of acute serious liver injury.

Immune-mediated myositis (an immune response affecting muscles) was observed in patients with a deletion mutation in the DMD gene that is contraindicated. Patients with certain mutation deletions (in exons 1 to 17 and/or exons 59 to 71) may be at risk for a severe immune-mediated myositis reaction. Caregivers should contact a healthcare provider immediately if the patient experiences any unexplained increased muscle pain, tenderness, or weakness, including difficulty swallowing, breathing, or speaking, as these may be symptoms of myositis.

Myocarditis (inflammation of the heart) has been observed within days following ELEVIDYS infusion. The patient’s doctor will conduct weekly blood tests for the first month after treatment to evaluate troponin-I (a cardiac protein that can detect damage to muscle cells in the heart). Caregivers should contact a healthcare provider immediately if the patient begins to experience chest pain and/or shortness of breath. More frequent monitoring may be required if the patient has cardiac symptoms.

Patients need to have blood tests to ensure that they do not have antibodies that may prevent them from being able to receive ELEVIDYS, as introducing the gene therapy could increase the risk of a severe allergic reaction or prevent desired therapeutic levels. Treatment with ELEVIDYS is not recommended for patients who have high antibodies to the vector, the part of gene therapy used to deliver ELEVIDYS.

Due to the need to follow a corticosteroid regimen, an infection (such as cold, flu, gastroenteritis [stomach flu], otitis media [ear infection], bronchiolitis [respiratory infection], etc) before or after ELEVIDYS infusion could lead to more serious complications. Caregivers should contact a healthcare provider immediately if they see any symptoms suggestive of infection, such as coughing, wheezing, sneezing, runny nose, sore throat, or fever.

Are there any considerations for vaccination schedules and ELEVIDYS?
Patient vaccinations should be up to date with current immunization guidelines. Vaccinations should be received at least 4 weeks prior to starting the corticosteroid regimen that is required before receiving ELEVIDYS.

Are there any precautions that need to be considered when handling a patient’s bodily waste?
Vector shedding of ELEVIDYS occurs primarily through body waste. Patients and caregivers should use proper hand hygiene, such as hand washing when coming into direct contact with patient body waste. Place potentially contaminated materials that may have the patient’s bodily fluids/waste in a sealable bag and dispose into regular trash. Precautions should be followed for 1 month after ELEVIDYS infusion.

What are the possible or likely side effects of ELEVIDYS?
The most common side effects that occurred in patients treated with ELEVIDYS were vomiting, nausea, liver injury, fever, and decreased platelet counts.

The safety information provided here is not comprehensive. Talk to the patient’s doctor about any side effects that bother the patient or that don’t go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).